20
Participants
Start Date
September 29, 2008
Primary Completion Date
December 3, 2008
Study Completion Date
December 3, 2008
GSK598809
Two 175 mg doses of GSK598809 will be given.
Ethanol
A constant ethanol level of 0.6 g·L-1 for five hours will be given to the subjects intravenously. This level shows significant CNS effects, without causing too many inadvertent events. Furthermore this level is considered safe as it is just above the legal driving limit in the Netherlands (i.e. 0.5 g·L-1) and these levels are routinely achieved during social drinking. Moreover, this level leaves enough room for CNS-impairment without compromising safety, in case of a (supra-) addictive drug-alcohol interaction.
GSK Investigational Site, Leiden
Lead Sponsor
GlaxoSmithKline
INDUSTRY